Unknown

Dataset Information

0

Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein.

ABSTRACT: Antibody-photosensitizer chemical conjugates are used successfully to kill cancer cells in photodynamic therapy. However, chemical conjugation of photosensitizers presents several limitations, such as poor reproducibility, aggregation, and free photosensitizer impurities. Here, we report a fully genetically encoded immunophotosensitizer, consisting of a specific anti-p185(HER-2-ECD) antibody fragment 4D5scFv fused with the phototoxic fluorescent protein KillerRed. Both parts of the recombinant protein preserved their functional properties: high affinity to antigen and light activation of sensitizer. 4D5scFv-KillerRed showed fine targeting properties and efficiently killed p185(HER-2-ECD)-expressing cancer cells upon light irradiation. It also showed a remarkable additive effect with the commonly used antitumor agent cisplatin, further demonstrating the potential of the approach.

SUBMITTER: Serebrovskaya EO 

PROVIDER: S-EPMC2695119 | biostudies-literature | 2009 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein.

Serebrovskaya Ekaterina O EO   Edelweiss Eveline F EF   Stremovskiy Oleg A OA   Lukyanov Konstantin A KA   Chudakov Dmitry M DM   Deyev Sergey M SM  

Proceedings of the National Academy of Sciences of the United States of America 20090520 23

Antibody-photosensitizer chemical conjugates are used successfully to kill cancer cells in photodynamic therapy. However, chemical conjugation of photosensitizers presents several limitations, such as poor reproducibility, aggregation, and free photosensitizer impurities. Here, we report a fully genetically encoded immunophotosensitizer, consisting of a specific anti-p185(HER-2-ECD) antibody fragment 4D5scFv fused with the phototoxic fluorescent protein KillerRed. Both parts of the recombinant p  ...[more]

Similar Datasets

Unknown Photoimmunotherapy Using Cationic and Anionic Photosensitizer-Antibody Conjugates against HIV Env-Expressing Cells.
| S-EPMC7730620 | biostudies-literature
Unknown Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen.
| S-EPMC3988171 | biostudies-literature
Unknown Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein.
| S-EPMC10941411 | biostudies-literature
Unknown Assessing Photosensitizer Targeting Using Meso-Tetra(Carboxyphenyl) Porphyrin.
| S-EPMC6017280 | biostudies-literature
Unknown Highly versatile cancer photoimmunotherapy using photosensitizer-conjugated avidin and biotin-conjugated targeting antibodies.
| S-EPMC6858743 | biostudies-literature
Unknown Site-specific modification of ED-B-targeting antibody using intein-fusion technology.
| S-EPMC3154154 | biostudies-literature
Unknown Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.
| S-EPMC6774808 | biostudies-literature
Unknown Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1.
| S-EPMC3513587 | biostudies-literature
Clinical A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer
| 180 | ecrin-mdr-crc
Unknown Enhanced Intracellular Photosensitizer Uptake and Retention by Targeting Viral Oncoproteins in Human Papillomavirus Infected Cancer Cells and Cancer Stem Cells.
| S-EPMC9867367 | biostudies-literature